Overview

IFN-beta 1b and Remdesivir for COVID19

Status:
Recruiting

Trial end date:
2021-09-30

Target enrollment:

Participant gender:

Summary

A 5-day combination of interferon β-1b and remdesivir will expedite the recovery, suppress the viral load and shorten hospitalisation in patients with SARS-CoV-2 infection compare to the control arm

Phase:

Phase 2

Details

Lead Sponsor:

The University of Hong Kong

Treatments:

Interferon beta-1b
Interferon-beta
Interferons
Remdesivir